Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go

References

• 1. Mehta K, Patel K, Parikh RA. Immunotherapy in genitourinary malignancies. J. Hematol. Oncol. 10, 95 (2017).
  MedlineGoogle Scholar
• 2. Gevaert T, Montironi R, Lopez-Beltran A et al. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Semin. Cancer Biol. 52(Pt 2), 216–227 (2018).
  Medline CASGoogle Scholar
• 3. American Association for Cancer Research. Three drugs approved for urothelial carcinoma by FDA | Cancer Discovery. (2017) http://cancerdiscovery.aacrjournals.org/content/7/7/659
  Google Scholar
• 4. Kourie HR, Klastersky J. Immune checkpoint inhibitors side effects and management. Immunotherapy 8, 799–807 (2016).
  CASGoogle Scholar
• 5. Goldstein DA. Financial toxicity in cancer care – edging toward solutions. Cancer 123, 1301–1302 (2017).
  MedlineGoogle Scholar
• 6. US FDA. FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients (2018). www.fda.gov/drugs/informationondrugs/approveddrugs/ucm612484.htm
  Google Scholar
• 7. Necchi A, Anichini A, Raggi D et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, Phase II study. J. Clin. Oncol. 36, 3353–3360 (2018).
  Medline CASGoogle Scholar
• 8. Rijnders M, van der Veldt AAM, Zuiverloon TCM et al. PD-L1 antibody comparison in urothelial carcinoma. Eur. Urol. 75(3), 538–540 (2019).
  Medline CASGoogle Scholar
• 9. Eckstein M, Erbenb P, Kriegmair MC et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur. J. Cancer 106, 234–243 (2019).
  Medline CASGoogle Scholar
• 10. Gevaert T, Eckstein M, Montironi R et al. PD-L1 antibody comparison in urothelial carcinoma. Eur. Urol. doi:10.1016/j.eururo.2019.01.038 (2019) (In Press).
  MedlineGoogle Scholar
• 11. Lerner SP, McConkey DJ, Hoadley KA et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer 2(1), 37–47 (2016).
  MedlineGoogle Scholar
• 12. Robertson AG, Kim J, Al-Ahmadie H et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171(3), 540–556.e25 (2017).
  Medline CASGoogle Scholar
• 13. Kim J, Kwiatkowski D, McConkey DJ et al. The Cancer Genome Atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur. Urol. 75(6), 961–964 (2019).
  Medline CASGoogle Scholar
• 14. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, Phase II trial. Lancet Lond. Engl. 387, 1909–1920 (2016).
  Medline CASGoogle Scholar
• 15. Teo MY, Seier K, Ostrovnaya I et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685–1694 (2018).
  Medline CASGoogle Scholar
• 16. Mariathasan S, Turley SJ, Nickles D et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
  Medline CASGoogle Scholar
• 17. Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP. Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur. Urol. 75(3), 423–432 (2019).
  Medline CASGoogle Scholar
• 18. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492), 315–322 (2014).
  MedlineGoogle Scholar
• 19. Balar AV, Galsky MD, Rosenberg JE et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, Phase II trial. Lancet 389, 67–76 (2017).
  Medline CASGoogle Scholar
• 20. Massari F, Mollica V, Di Nunno V et al. The human microbiota and prostate cancer: friend or foe? Cancers (Basel) 11(4), pii:E459 (2019).
  Google Scholar
• 21. Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur. J. Immunol. 45, 17–31 (2015).
  Medline CASGoogle Scholar
• 22. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369–2379 (2016).
  Medline CASGoogle Scholar
• 23. Reid G. Microbes in food to treat and prevent disease. Exp. Rev. Precision Med. Drug Develop. 3(2), 79–81 (2018).
  Google Scholar
• 24. Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science 336, 1255–1262 (2012).
  Medline CASGoogle Scholar
• 25. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13, 260–270 (2012).
  Medline CASGoogle Scholar
• 26. Schwabe RF, Jobin C. The microbiome and cancer. Nat. Rev. Cancer 13, 800–812 (2013).
  Medline CASGoogle Scholar
• 27. Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat. Rev. Cancer 17, 271–285 (2017).
  Medline CASGoogle Scholar
• 28. Brandi G, Dabard J, Raibaud P et al. Intestinal microflora and digestive toxicity of irinotecan in mice. Clin. Cancer Res. 12(4), 1299–1307 (2006).
  Medline CASGoogle Scholar
• 29. Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371), 91–97 (2018).
  Medline CASGoogle Scholar
• 30. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359(6382), 1366–1370 (2018).
  Medline CASGoogle Scholar
• 31. Mazzucchelli R, Gasparrini S, Galosi AB et al. Immunotargeting and personalized therapies in genitourinary cancers. Future Oncol. 12(16), 1853–1856 (2016).
  CASGoogle Scholar
• 32. Lovitch SB, Rodig SJ. The role of surgical pathology in guiding cancer immunotherapy. Annu. Rev. Pathol. 11, 313–341 (2016).
  Medline CASGoogle Scholar